Healthy volunteers test new cancer Drug's body processing
NCT ID NCT07044271
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study enrolled 120 healthy volunteers to measure how much olomorasib enters the bloodstream and how quickly the body eliminates it. Participants took a single dose of the drug by mouth and stayed overnight at the research center for 10 nights over about 7 weeks. The results will guide future dosing for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olomorasib (LY3537982)
- What this could lead to
- If successful, this study will help determine the right dose and formulation of olomorasib for future trials in patients.
- What could go wrong
- This is an early-stage study in healthy people, not patients. Results may not predict how the drug works in people with disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON
Salt Lake City, Utah, 84124, United States
-
ICON Early Phase Services
San Antonio, Texas, 78209, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test